Highlights Sarepta Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-25 EDT			5-day change	1st Jan Change
158.1 ^USD	-3.53%		+34.50%	+63.91%

06-24	Morgan Stanley Adjusts Sarepta Therapeutics' Price Target to $200 From $165, Keeps Overweight Rating	MT
06-24	Evercore ISI Raises Price Target on Sarepta Therapeutics to $185 From $139, Maintains In Line Rating	MT

Health Care Stocks Boosted By Duchenne MS Drug -- Health Care Roundup	06-21	DJ
Sector Update: Health Care Stocks Gain in Late Afternoon	06-21	MT
S&P, Nasdaq edge down as Nvidia declines for second day	06-21	RE
Top Midday Gainers	06-21	MT
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	06-21	MT
Sarepta Therapeutics' Gets Label Expansion for Elevidys in 'Best-case Scenario,' BofA Securities Says	06-21	MT
S&P 500, Nasdaq lower as semiconductor shares weigh	06-21	RE
Sarepta surges as investors cheer expanded use of gene therapy	06-21	RE
Sector Update: Health Care Stocks Steady Premarket Friday	06-21	MT
Sector Update: Health Care	06-21	MT
Wavering Tech Rally Pushes Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Friday	06-21	MT
Top Premarket Gainers	06-21	MT
Sarepta surges as investors cheer expanded use of gene therapy	06-21	RE
Futures Down Pre-Bell as Traders Wait for Market Direction Cues; Asia, Europe Fall	06-21	MT
Wall Street futures edge lower ahead of business survey data	06-21	RE
Sarepta Stock Jumps on Expanded FDA Approval for Duchenne Muscular Dystrophy Gene Therapy	06-21	MT
Sarepta Therapeutics Gets Expanded Label FDA Approval for Duchenne Muscular Dystrophy; Shares Soar Premarket	06-21	MT
Sarepta Therapeutics Gets Expanded US FDA Approval for Treatment of Duchenne Muscular Dystrophy; Shares Soar After Hours	06-20	MT
US FDA approves expanded use of Sarepta's Duchenne gene therapy; shares jump	06-20	RE
US FDA allows expanded use of Sarepta's Duchenne gene therapy	06-20	RE

No results for this search